We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
-7.07%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$393M
AUM Growth
-$29.9M
Cap. Flow
+$15.9M
Cap. Flow %
4.04%
Top 10 Hldgs %
52.55%
Holding
90
New
6
Increased
29
Reduced
20
Closed
8
Avg Time Held
11.3 quarters
Top 10 Avg Time Held
7.2 quarters
Top 20 Avg Time Held
11.7 quarters

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$5.71M
2
TELA icon
TELA Bio
TELA
+$4.05M
3
KROS icon
Keros Therapeutics
KROS
+$2.94M
4
BPMC icon
Blueprint Medicines
BPMC
+$2.56M
5
BCAX icon
Bicara Therapeutics
BCAX
+$2.2M

Top Sells

Rank Stock Value
1
VKTX icon
Viking Therapeutics
VKTX
+$3.48M
2
SLRN icon
ACELYRIN
SLRN
+$2.49M
3
AQST icon
Aquestive Therapeutics
AQST
+$2.13M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$1.3M
5
AXGN icon
Axogen
AXGN
+$1.26M

Sector Composition

Rank Sector Weight
1 Healthcare 86.33%
2 Miscellaneous 13.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XBI icon
1
State Street SPDR S&P Biotech ETF
XBI
$9.71B
$35.8M 9.1%
397,505
-4,000
-1% -$388K
2022 Q1
11 quarters
STXS icon
2
Stereotaxis
STXS
$106M
$31.2M 7.93%
13,680,554
– –
2013 Q2
46 quarters
RVMD icon
3
Revolution Medicines
RVMD
$40.4B
$27.6M 7.02%
631,176
+113,182
+22% +$5.71M
2020 Q4
16 quarters
ATRC icon
4
AtriCure
ATRC
$2.89B
$19.6M 4.98%
641,673
– –
2013 Q2
46 quarters
MRUS icon
5
DELISTED
Merus
MRUS
$19M 4.83%
451,804
+39,231
+10% +$1.88M
2021 Q1
15 quarters
CYTK icon
6
Cytokinetics
CYTK
$8.57B
$18.7M 4.76%
398,100
– –
2021 Q3
13 quarters
ASND icon
7
Ascendis Pharma A/S
ASND
$14.7B
$14.2M 3.62%
103,355
+13,783
+15% +$1.81M
2021 Q4
12 quarters
AXGN icon
8
Axogen
AXGN
$2.12B
$14M 3.55%
846,882
-89,012
-10% -$1.26M
2021 Q4
12 quarters
IBB icon
9
iShares Biotechnology ETF
IBB
$10.2B
$13.6M 3.44%
102,500
– –
2016 Q4
32 quarters
BPMC icon
10
DELISTED
Blueprint Medicines
BPMC
$13.1M 3.32%
149,763
+28,000
+23% +$2.56M
2016 Q4
32 quarters
IDYA icon
11
IDEAYA Biosciences
IDYA
$3.31B
$12.8M 3.26%
498,827
+27,417
+6% +$776K
2020 Q3
17 quarters
XENE icon
12
Xenon Pharmaceuticals
XENE
$3.33B
$10.7M 2.73%
273,739
– –
2015 Q3
37 quarters
NBIX icon
13
Neurocrine Biosciences
NBIX
$13.7B
$9.78M 2.48%
71,615
+2,000
+3% +$247K
2016 Q1
35 quarters
DAWN icon
14
DELISTED
Day One Biopharmaceuticals
DAWN
$9.27M 2.36%
731,363
-19,000
-3% -$264K
2023 Q2
6 quarters
BHVN icon
15
Biohaven
BHVN
$1.72B
$8.23M 2.09%
220,235
+33,105
+18% +$1.54M
2022 Q3
9 quarters
TNDM icon
16
Tandem Diabetes Care
TNDM
$1.16B
$8.04M 2.04%
223,208
+19,000
+9% +$643K
2023 Q2
6 quarters
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.25B
$7.17M 1.82%
542,002
+15,300
+3% +$262K
2020 Q2
18 quarters
KALV icon
18
DELISTED
KalVista Pharmaceuticals
KALV
$6.87M 1.75%
811,678
+88,000
+12% +$911K
2021 Q1
15 quarters
URGN icon
19
UroGen Pharma
URGN
$1.87B
$5.25M 1.33%
492,515
+33,600
+7% +$402K
2024 Q2
2 quarters
DXCM icon
20
DexCom
DXCM
$32.1B
$5.1M 1.3%
65,552
– –
2017 Q3
29 quarters
BCRX icon
21
BioCryst Pharmaceuticals
BCRX
$2.06B
$5.02M 1.28%
667,000
– –
2022 Q4
8 quarters
EWTX icon
22
Edgewise Therapeutics
EWTX
$3.94B
$5M 1.27%
187,140
-40,766
-18% -$1.3M
2022 Q1
11 quarters
TELA icon
23
TELA Bio
TELA
$48.1M
$4.35M 1.11%
+1,441,029
New +$4.05M
2024 Q4
0 quarters
PRQR icon
24
ProQR Therapeutics
PRQR
$209M
$4.15M 1.06%
1,567,561
+661,979
+73% +$2.1M
2023 Q1
7 quarters
KURA icon
25
Kura Oncology
KURA
$874M
$3.91M 0.99%
448,368
+40,000
+10% +$576K
2017 Q3
29 quarters
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, DAFNA Capital Management held 90 positions worth $393M, down 7.1% from $423M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DAFNA Capital Management deployed $15.9M of net new capital in Q4 2024, opening 6 new positions and adding to 29 existing holdings. Its largest new stake was TELA Bio: 1,441,029 shares worth $4.35M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 86% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Viking Therapeutics, an estimated $3.48M trimmed.

  • DAFNA Capital Management's largest Q4 2024 buy was TELA Bio: 1,441,029 shares worth $4.35M.
  • DAFNA Capital Management added most to Revolution Medicines in Q4 2024, an estimated $5.71M increase.
  • DAFNA Capital Management's biggest Q4 2024 reduction was Viking Therapeutics, cutting an estimated $3.48M.
  • DAFNA Capital Management fully exited Nyxoah in Q4 2024, selling an estimated $1.03M.
  • DAFNA Capital Management's ten largest holdings make up 53% of its $393M portfolio in Q4 2024.
  • DAFNA Capital Management opened 6 new positions and closed 8 in Q4 2024.
  • DAFNA Capital Management's portfolio value fell 7.1% quarter-over-quarter to $393M.

Based on DAFNA Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.